Immune checkpoint inhibitors and dermatologic procedures: a retrospective review of postoperative complications.

In 2011, with ipilimumab, immune checkpoint inhibitors (ICI) gained FDA approval for the treatment of metastatic melanoma [[4]]. Collected variables included patient demographics, ICI indication, surgery indication, postoperative course including complications, and length of follow-up. Results here suggest that ICI therapy does not substantially increase the rate of complications in patients undergoing dermatologic procedures [[2]]. [Extracted from the article]